Provided by Tiger Fintech (Singapore) Pte. Ltd.

Global Partners LP

53.95
-0.7600-1.39%
Post-market: 53.950.00000.00%17:05 EDT
Volume:60.81K
Turnover:3.30M
Market Cap:1.82B
PE:22.39
High:54.92
Open:54.35
Low:53.84
Close:54.71
Loading ...

Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs

ACCESSWIRE
·
26 Nov 2024

Drug Compounders Fight Drugmaker Efforts to Push Them Out of Market for GLP-1 Medications

MT Newswires Live
·
26 Nov 2024

Allurion launches compounded GLP-1 program as FDA aims to end access

Yahoo Finance
·
26 Nov 2024

Strategic Expansion and Innovation: Allurion Technologies’ Leap into the GLP-1 Market

TIPRANKS
·
26 Nov 2024

Lexaria Bioscience completes dosing for GLP-1 human pilot study #3

TIPRANKS
·
25 Nov 2024

Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled

ACCESSWIRE
·
25 Nov 2024

BRIEF-Allurion Launches in the US with its First AI-Native Compounded GLP-1 Program

Reuters
·
25 Nov 2024

Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist

Business Wire
·
22 Nov 2024

Hims & Hers jumps as status report says patients unable to obtain branded GLP-1s

TIPRANKS
·
22 Nov 2024

ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria’s 12-Week GLP-1, Diabetes Animal Study

ACCESSWIRE
·
20 Nov 2024

Lexaria Bioscience signs contract for DehydraTECH GLP-1 biodistribution study

TIPRANKS
·
14 Nov 2024

Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study

ACCESSWIRE
·
14 Nov 2024

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

GlobeNewswire
·
14 Nov 2024

Americans Face Challenges to Access GLP-1 Medication -- Market Talk

Dow Jones
·
14 Nov 2024

Lexaria Bioscience Advances GLP-1 Study

TIPRANKS
·
14 Nov 2024

Altimmune’s pemvidutide looks differentiated among GLP-1s, says H.C. Wainwright

TIPRANKS
·
14 Nov 2024